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Obesity, metabolic syndrome, and type-2 diabetes
mellitus are 3 interrelated conditions that share a number
of pathophysiological mechanisms and that are frequently
observed to lead, in succession, to cardiovascular
complications. The fact that their prevalence is increasing
alarmingly should prompt all healthcare professionals
urgently to implement measures to prevent these
complications. The most effective, though also the least
adopted, are those related to lifestyle modification. Drug
treatment targeted at controlling risk factors (eg,
hypertension, dyslipidemia, and thrombophilia), metabolic
abnormalities, and excess weight is also necessary.
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Obesidad, síndrome metabólico y diabetes:
implicaciones cardiovasculares y actuación
terapéutica
Obesidad, síndrome metabólico y diabetes mellitus tipo
2 son tres enfermedades interrelacionadas que compar-
ten mecanismos de aparición y evolución y con frecuen-
cia se van combinando sucesivamente y ocasionan com-
plicaciones cardiovasculares. Su prevalencia crece
alarmantemente y debería impeler a los profesionales de
la salud y a los gestores a implantar medidas urgentes
para prevenir la aparición de complicaciones. Las más
eficaces, aunque menos practicadas, son las relaciona-
das con el estilo de vida. También son necesarios trata-
mientos farmacológicos destinados al control de los fac-
tores de riesgo (hipertensión, dislipemias, trombofilia), las
alteraciones metabólicas y el propio exceso de peso.
Palabras clave: Diabetes. Síndrome metabólico. Obesi-
dad.
INTRODUCTION 
Few will disagree that obesity is fast becoming the
21st century´s most serious health problem. It is a
condition which begins in childhood, flourishes in
adulthood, and leads to multiple health problems. Genetic
and molecular factors, other exacerbating circumstances,
and environmental and behavioral triggers all play a part
in its development and determine its treatment.1 Type 2
diabetes mellitus (DM2) is a metabolic disease arising
from flaws in the action of insulin in the peripheral tissues.
The resulting chronic hyperglycemia is accompanied by
damage to organs, particularly the eyes, kidneys, and
heart, as well as to nerves and arteries.
The present article reviews the definitions and
physiopathology of obesity and the related diseases of
metabolic syndrome (MS) and DM2. It reviews the
cardiovascular implications and complications of these
diseases as well as preventive and therapeutic measures
against these conditions and the accompanying
cardiovascular risk.
DEFINITIONS 
Obesity 
Obesity is defined as an excess of corporal adiposity.
For practical reasons, body weight has been used as an
indirect measure of the degree of adiposity as the latter
is not easy to measure with the usual tests. In the eighties,
the concept of body mass index (BMI) was introduced
and cut points were established to define overweight and
obesity in adult men and women.2 Values were later
established for children and adolescents (Table 1).3,4
Independent of the fact that high BMI values are
associated with adverse risk profiles for morbidity and
mortality, particularly in relation to DM2 and
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atherothrombotic cardiovascular disease (CVD), various
sub-types of obesity have been described which
complement the apparent dose-response relationship
between BMI and its impact on health. The most classic
sub-types are android obesity (abdominal) and gynoid
obesity (gluteal obesity).5,6 Less well-known sub-types
are, however, also of interest. For example, a phenotype
corresponding to metabolically obese normal-weight
(MONW) individuals has been reported. These individuals
have a normal BMI together with some of the
characteristics of obese individuals such as insulin
resistance, central adiposity, low levels of high density
lipoproteins (HDL) and high levels of triglycerides, and
high blood pressure (HBP).7 At the same time,
metabolically healthy obese (MHO) individuals have
also been identified.8 These individuals have BMI>30,
but none of the metabolic alterations which are typical
of obese individuals. 
The existence of these 2 “paradoxical” sub-types led
to several studies over the last 2 decades which aimed to
metabolically characterize and quantify visceral adipose
tissue as opposed to subcutaneous adipose tissue. These
studies showed that the quantity of visceral adipose tissue
is directly correlated in both men and women with a
seriously altered metabolic risk profile which precedes
the development of DM2 and cardiovascular disease.
Therefore, although it is true that obesity increases the
risk of chronic disease, it seems clear that patients with
visceral obesity form a sub-group of individuals with the
most serious metabolic alterations. It has been
demonstrated, for instance, that the regional accumulation
of fatty tissue in the visceral deposits is a more reliable
predictor of cardiovascular risk than the total quantity of
body fat. The multi-country INTERHEART case-control
study confirmed the importance of adiposity, and
particularly abdominal adiposity, as a risk factor for acute
myocardial infarction.9
Metabolic Syndrome
In recent years, MS has caused an authentic revolution
in vascular risk stratification and has become one of the
most widely used concepts within the health sciences. It
describes the accumulation within an individual patient
of several very prevalent conditions in western countries,
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all of which are risk factors for CVD and DM2. The 2
underlying mechanisms of MS are abdominal adiposity
and insulin resistance.10 it is exacerbated by age, genetic
conditioning, and an inappropriate lifestyle which includes
physical inactivity and the consumption of high calorie,
high-fat foods, concentrated carbohydrates, and salt.
These metabolic alterations occur simultaneously more
frequently than would be expected by chance and the
concurrence of several factors increases cardiovascular
risk over and above the risk associated with the individual
factors alone.11
There are numerous definitions of MS. Although all
of the classifications include the syndrome’s essential
components, they differ on details or on whether to include
components which are difficult to measure. The two most
widely used definitions are those of the International
Diabetes Federation12 classification and the definition
included in the latest revision of the ATP-III (Adult Tre-
atment Panel III of the United States’National Cholesterol
Education Program).13 The 2 classifications are very
similar and are summarized in Table 2.
The risk factors constituting MS are atherogenic
dyslipidemia, high blood pressure, glucose metabolism
disorders, and proinflammatory and prothrombotic states,
ie all of the classic CVD risk factors except for smoking,
family history, and age. Atherogenic dyslipidemia includes
higher levels of apolipoprotein B containing lipoproteins
and triglycerides, a greater number of small low density
lipoprotein (LDL) particles (with a higher atherogenic
cholesterol content), and low concentrations of HDL.
Although they are not included in the definition of MS,
other biological markers can sometimes be useful, such
as those related to adipose tissue (percentage of abdominal
fat using digital tomography, leptin/adiponectin ratio),
other markers of dyslipidemia (apolipoprotein B or size
of LDL particles), endothelial dysfunction (measured by
the vasodilatory response in the humeral artery),
inflammation markers (C-reactive protein) or thrombosis
markers (high fibrinogen or plasminogen activator
inhibitor–1)13 (Table 3).
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ABBREVIATIONS
BMI: body mass index
CVD: cardiovascular disease
DM2: type 2 diabetes mellitus
HBP: high blood pressure
HDL: high density lipoproteins
MS: metabolic syndrome
TABLE 1. Definitions of Obesity According to Body
Mass Index3,4
Category Children and Adolescentsa Adultsb
Underweight <p5 <18.5
Normal weight p5-85 18.5-24.9
Risk of overweight p85-90 —
Overweight >p95 25-29.9
Grade 1 obesity — 30-34.9
Grade 1 obesity — 35-39.9
Morbid obesity — 40-49.9
Super-morbid obesity — >50
aBMI percentile by age group (Centers for Disease Control and Prevention).3
bBody mass index (BMI) = weight (in kg)/height (in m) squared (NIH and
OMS)4; p = percentile.
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Diabetes 
The American Diabetes Association diagnostic criteria
for diabetes are clear14: a) casual plasma glucose level
>200 mg/dL in a patient with characteristic symptoms
(“casual” is defined as an analysis performed at any time
of day independently of the time of the last food intake),
polyuria, polydipsia, and weight loss; or b) fasting glucose
level >126 mg/dL confirmed in 2 determinations (fasting
is defined as the absence of caloric intake during at least
8 h); or c) plasma glucose values 2 h after an oral glucose
load >200 mg/dL; the test should be performed according
to the WHO guidelines, using a standard drink containing
the equivalent of 75 g of anhydrous glucose dissolved in
water. 
As well as diabetes, other pre-diabetic syndromes
which are reflected in the concept of glucose metabolism
disorders are diagnosed in patients who do not meet the
criteria for a diagnosis of diabetes but who have higher
than normal basal glucose levels or after loading. Figure
1 summarizes the criteria for the diagnosis of altered
basal glucose values and glucose intolerance.14
PHYSIOPATHOLOGICAL ASPECTS 
Details on the mechanisms underlying the type of
vascular injuries which are produced by the 3 inter-related
conditions under consideration, ie obesity, MS, and DM2
go beyond the scope of this review article. Few brief
pointers are provided.
Obesity is a risk factor for atherosclerosis due to a
variety of mechanisms which are summarized in Figure
2. Insulin resistance, which is the common link with MS,
leads to glucose metabolism disorders, dyslipidemia,
high blood pressure, endothelial dysfunction, and
inflammation induced by cytokine imbalance. The latter,
ie an excess of harmful cytokines (interleukins 6 and 18,
tumor necrosis factor alpha, and leptin being among the
most important) combined with a scarcity of protector
cytokines (adiponectin).15
Central adiposity, one of the principal characteristics
of MS, provides the foundation for the portal/visceral
theory, which suggests that the increase in adiposity,
particularly in visceral deposits, leads to an increase in
the flow of free fatty acids and the inhibition of insulin
action. The large quantity of non-sterified fatty acids
reduces the use of glucose by skeletal muscle, stimulates
the hepatic production of very low-density lipoproteins
and glucose, and propitiates the acute secretion of insulin.
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TABLE 2. Diagnostic Criteria for Metabolic Syndrome
International Diabetes Federation (2005)12
Central adiposity (waist circumference for European population: 
males, >94; females, >80 cm) and 2 or more of: 
Triglycerides >150 mg/dL or specific treatment 
HDL<40 (males) or <50 mg/dL (females) or treatment
Blood pressure >130/85 mm Hg or treatment for hypertension
Baseline blood glucose >100 mg/dL or prior diagnosis of 
diabetes
National Cholesterol Education Program (ATP-III) (2002)13
Three or more of the following criteria:
Fasting glucose >110 mg/dL [100]
Blood pressure >130/85 mm Hg [or treatment]
Triglycerides >150 mg/dL [or treatment]
HDL cholesterol [or treatment]
<40 mg/dL in males
<50 mg/dL in females
Abdominal adiposity 
Waist >102 cm (males)
Waist >88 cm (females)
HDL indicates high density lipoproteins.
The details in square brackets were added in 2005 to adapt to the IDF definition.
TABLE 3. Other Components of Metabolic Syndrome
Criteria Markers
Adiposity Visceral adiposity (TD)
Nonalcoholic steatohepatitis
Adipose tissue markers Leptin, adiponectin
Dyslipidemia Apolipoprotein B
Size of LDL particles
Insulin resistance Direct estimation
Oral glucose tolerance test
Endothelial dysfunction Humeral vasodilatory response
Albuminuria
Inflammation or thrombosis PCR, TNFα, IL-6
PAI-1, fibrinogen
IL indicates interleukin; PAI, plasminogen activator inhibitor; CRP, C-reactive
protein; CD, computerized tomography; TNF, tumor necrosis factor.
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Figure 1. Concept of glucose metabolism disorder (American Diabetes
Association criteria14). Diabetes is diagnosed when several determinations
of basal glucose levels (after 12 h of fasting) exceed 126 mg/dL or if
glucose levels 2 h after an oral load of 75 g of glucose (OGL) exceed 200
mg/dL. Glucose levels of 100 to 126 mg/dL indicate a diagnosis of
“abnormal glucose levels” (AGL) and between 140 and 200 mg/dL after
OGL indicate “glucose intolerance” (GI). 
Document downloaded from http://www.revespcardiol.org, day 05/06/2012. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
The lipotoxic effect in the pancreatic beta cells caused
by free fatty acids over the long term could be part of
the connection between obesity, insulin resistance, and
the development of DM2. However, the portal theory has
been placed in quarantine and there is some evidence
that it is unable to explain, by itself, all of the metabolic
anomalies present in abdominally obese individuals.16,17
There was considerable debate as to whether MS
increases the risk of cardiovascular disease to a greater
degree than the sum of its individual parts, though it has
now clearly been shown that this is the case. In the first
place, epidemiological studies have demonstrated that
the degree of risk involved when multiple risk factors
are present is greater than the sum of the risks attributable
to each individual factor; in other words, under these
circumstances, risk increases geometrically rather than
linearly. In the second place, the algorithms habitually
used to calculate cardiovascular risk do not include several
metabolic factors which have been shown to independently
increase the risk of vascular complications. These include
the prothrombotic state, inflammatory status, and
hypertriglyceridemia. The additional risk associated with
these factors exceeds that attributed to conventional risk
factors. In the third place, some of the risk attributed to
conventional factors probably derives from factors which
have not been considered or measured. Finally, as MS
progresses and often culminates in DM2, the risks
associated with the latter should be added to those already
mentioned. The evolution of MS in terms of its
pathological consequences are shown in Figure 3.16
Figure 4 summarizes the latest theories regarding the
relationship between obesity and MS, which is posited
as a dysfunction of adipose tissue with insulin resistance
appearing later when compensatory response mechanisms
have been exhausted.17
From what has been described here, it is clear that MS
is a first order risk factor for atherothrombotic
complications. Its presence or absence should therefore
be considered an indicator of long-term risk. On the other
hand, over the short term (5-10 years) risk is better
calculated using the classical algorithms (Framingham,
SCORE, REGICOR), as they include age and sex, total
cholesterol or LDL, and smoking.16
The basic cardiovascular complications produced by
hyperglycemia in DM2 are microangiopathic disease
(diabetic nephropathy, retinopathy, and diabetic
neuropathy) and CVD (diabetic macroangiopathy). These
include coronary heart disease and stroke as the main
complications, although peripheral arterial disease is also
common and tends to be more serious (higher indices of
serious ischemia and amputations) when it is cause by
diabetes than when it is caused by other mechanisms.
Cardiovascular diseases is the most important
complications of DM2, both in clinical and numerical
terms and represent up to 80% of the macrovascular
complication attributed to the disease.18,19 Apart from
hyperglycemia, other risk factors (notably high blood
pressure, dyslipidemia, and obesity) are also very prevalent
in diabetic patients. 
Micro- and macroangiopathy exist side by side and
their harmful effects are multiplied in DM2. Damage to
the endothelium produced by accumulation of
glucosilation sub-products, reduced production of nitric
oxide, and endothelial inflammation are among the most
characteristic mechanisms involved in the process.
SOME EPIDEMIOLOGICAL DATA 
Over the last 50 years, people have experienced drastic
changes in their environment, behavior, and lifestyles.
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Figure 2. Diagram of atherosclerosis
pathogenesis in obesity. The three main
mechanisms are insulin resistance,
increased free fatty acids, and cytokine
imbalance. FFA indicates free fatty acids;
HDL-C, high density lipoprotein cholesterol;
LDL-C, low density lipoprotein cholesterol;
DM2, type 2 diabetes mellitus; HBP, high
blood pressure; GI, glucose intolerance.
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These changes have led to the alarming increase in
incidence of diabetes and obesity.20 The substitution of
manual labor by mechanized processes, increased
consumption of “empty calories,” the globalization of
technology, and improvements in transport are some of
the factors which have led to this pandemic.21 One of the
most recent studies into the prevalence of overweight,
which was carried out by the WHO and the International
Obesity Task Force, found that the worldwide prevalence,
after adjusting for ethnic differences, was 1700 million
overweight individuals, of which 312 million were
obese.15,20 The trend in the obesity figures means that it
is now considered one of the greatest health threats in
the developed world. Data from successive cohorts of
the National Health and Nutrition Examination Survey
(NHANES)22 show that the mean waist circumference
of adults in the USA increased by 3.1 cm between the
1988-1994 and 1999-2000 surveys. After adjusting by
age, the largest increases in waist circumference were
observed in the youngest age group (20-29 years). Over
the past 20 years, prevalence rates for obesity have tripled
in developing countries which have adopted western
lifestyles. These have shown the typical patterns of reduced
physical activity and over consumption of high energy-
density meals. The last survey into the prevalence of
overweight in CVD by the European Society of
Cardiology (Euro-Heart Survey) was carried out in 8547
patients with chronic ischemic heart disease and found
a prevalence of overweight (BMI>25) of 83% and of
obesity (BMI>30) of 38%. Overall, 55% of the sample
had central obesity (waist circumference >102 cm in
men, >88 cm in women) (unpublished data). 
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metabolic syndrome (adapted from Haslam
et al16).
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Figure 4. Metabolic syndrome as a
dysfunction of adipose tissue (adapted
from Laclaustra et al17).
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There have been several studies into the prevalence of
obesity in the Spanish general population. For example,
Figure 5 shows data from the MESYAS register obtained
from 18 778 healthy members of the working population
(78% male).23
One of the reasons for the current interest in MS is its
high prevalence. In the Spanish MESYAS register of
healthy members of the working population, 12% were
found to have the condition (Figure 6).23 This compares
to figures of 22% for the Spanish general population,
41% for patients with heart disease in Spain, and 24%
of those included in the United States NHANES survey.22
Finally, the DM2 epidemic is expanding principally
in developed and developing countries. Estimates are not
very encouraging and have taken public health authorities
by surprise. Worldwide, the number of those with DM2
is expected to grow from the current 150 million to 220
million in 2010 and to 300 million in 2025.24 The great
majority will have DM2 associated with obesity and a
sedentary lifestyle. This trend towards an increased
prevalence of DM2 and obesity presents a real challenge
for public health systems practically the whole world
over and will continue to do so into the foreseeable future
(Figure 7).
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Figure 5. Prevalence of weight alterations in men (A) and women (B) in the MESYAS23 register of 18 778 healthy men and women.
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DIAGNOSTIC APPROACH 
Obesity and Metabolic Syndrome 
Diagnosis in individuals with obesity and MS should
take into account the progressive nature of these
conditions. In general, their evolution can be summarized
in 4 phases, beginning with the presence of certain causal
factors (central adiposity and insulin resistance, as well
as genetic factors). These give rise to the metabolic
alterations described above (high blood pressure,
dyslipidemia, and glucose metabolism disorders) which
in turn are followed by the development of vasculopathy.
This is initially subclinical but eventually manifests as
characteristic atherothrombotic complications and DM2
(Figure 3). Diagnosis should therefore not be limited to
determining the presence of metabolic alterations, but
should also explore the possibility of vasculopathic
complications.13
Given the high risk associated with both diseases over
the long term, it would seem logical to suggest that overall
cardiovascular risk be assessed in all obese individuals
or those with MS. Such an assessment should include
checking on the presence and magnitude of MS
components. Medium-term risk should be evaluated using
risk prediction models adapted whenever possible to the
local population, and the possibility of sub-clinical
vasculopathy should be investigated using the appropriate
procedures. 
Signs of asymptomatic vasculopathy can be studied
in all in vascular territories mostly affected by atherosclerosis
(Table 4).25 If coronary heart disease is suspected, stress
tests should be used to detect myocardial ischemia or
alterations in perfusion together with non-invasive
coronary angiographic imaging via multislice computed
tomography or the classical technique. The possibility
of an effect on cerebral blood flow can be studied by
determining the intima media thickness of the common
carotid artery, while the impact on peripheral circulation
is measured most precisely using abdominal ultrasound
to determine the diameter of the aorta. The ankle-brachial
index can also be used as a non-invasive method to detect
peripheral vascular disease, which correlates with vascular
risk. Other, more general signs of sub-clinical
vasculopathy are microalbuminuria and erectile
dysfunction.25
Diabetes 
Diabetes is now considered a vascular disease even
when it clinical complications are not present. This
approach is clearly important from the treatment point
of view, though it is more doubtful when it comes to
diagnosis, and has led to disagreement with the European
Society of Cardiology’s clinical practice guidelines on
diabetes and pre-diabetes which strongly recommend
that tests to detect myocardial ischemia are performed
on all patients with DM2.26
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Figure 7. Diabetes cases (in millions of
individuals) in 2000 and predicted for
2030.24
TABLE 4. Study of Sub-Clinical Vasculopathy
Territory Test
Coronary Tests of ischemia
Multislice computed tomography
Coronary angiography
Encephalic IMT carotid
Periphery Abdominal ultrasound
Ankle/brachial index
General Albuminuria
Erectile dysfunction
Endothelial function
IMT indicates intima media thickness.
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PREVENTIVE TREATMENT 
Table 5 provides a summary of the general approach
to treating the metabolic syndromes.13,27,28 The primary
objective is to prevent onset of CVD,29,30 though it is
equally important to delay or avoid onset of DM2 if it is
not already present.13
Life-Style 
Lifestyle is key to the treatment of DM2, MS, and
obesity.13,26 If all of these conditions are due to the
expression of a particular genetic predisposition
exacerbated by an inappropriate lifestyle, then the first
step in treatment is to modify that lifestyle. The three
basic components in any such improvement are diet,
exercise, and behavior. 
The first essential step is weight loss (Figure 5). This
apparently simple step (which is in fact the most difficult
to achieve and, therefore, the least frequently achieved)
has demonstrated numerous beneficial effects: it reduces
mortality, improves lipid profiles, reduces blood pressure
and left ventricle mass in hypertension, and it reduces
inflammation markers in DM2. Furthermore, in patients
with MS it has been shown that it slows progression to
DM2.31 The same beneficial effects have also been
observed in obese patients.32
As well as the quantitative aspect of a reduction in
caloric uptake, dietary composition can also affect vascular
health. Avoiding fats other than those from olive oil,
increasing the consumption of fruits, vegetables, and
whole-food cereals, avoiding industrially sweetened
products and fatty meats, and eating white and especially
blue fish are some of the recommendations in this regard
(Table 6).33
Exercise has similar beneficial effects in MS, obesity,
and DM2. As well as helping to achieve and maintain
weight loss, it also reduces all of the components of MS
and reduces the incidence of CVD.34
It may be stating the obvious to insist that patients
should be encouraged to give up smoking, but it is
not enough only to offer advice; health care
professionals should ensure they provide the requisite
support for stopping smoking at all levels of cardio-
vascular risk. 
Treatment of High Blood Pressure
According to the ADA and ESH/ESC guidelines,35
blood pressure targets in diabetes mellitus should be
<130/80 mm Hg. The same values are recommended for
patients with MS.13
Angiotensin converting enzyme (ACE) inhibitors have
demonstrated multiple beneficial effects on cardiovascular
complications and for that reason are considered the first
line, or preferred treatment for high blood pressure,
particularly when established or incipient kidney disease
is present.35,36 Some well-known studies have also shown
that calcium antagonists are effective against CVD.37 In
DM2 patients, either of these treatments could be
considered the most appropriate choice, alone or in
combination. Beta-blockers are indicated where coronary
artery disease or heart failure are present. Diuretics
showed a satisfactory anti-hypertensive effect in some
studies,38 though they also led to a worsened metabolic
status39 and have no effect on arterial rigidity. For these
reasons, beta-blockers and diuretics are considered
complementary to ACE inhibitors and calcium channel
blockers, with which they can be carefully used in
combination to achieve appropriate levels of blood
pressure control.
Lipid-Lowering Treatment
Lipid-lowering treatments are used based on the initial
levels of lipids in blood with the aim of reaching targets
set in international guidelines (Figure 8), ie LDL<100
mg/L, though a value of <70 mg/dL may be selected if
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TABLE 5. Overview of Treatment for Metabolic
Syndrome, Obesity, and Diabetes
Aspect Treatment Components
Essential Lifestyle Diet
Aerobic exercise
Complementary Vascular protectors drugs Hypotensive drugs
Lipid regulators
Blood glucose 
regulators 
Anti-thrombotics 
Adjunctive drugs Weight regulating 
drugs 
Complications Anti-ischemic drugs Calcium antagonists
Nitrates 
Others 
Revascularization Percutaneous 
Surgical 
TABLE 6. Dietary Components and Vascular Risk
Harmful Protective
Excess calories Mediterranean diet (fish, 
vegetables and fruit, olive oil, 
wine)
Saturated fats Vegetable steroles
Salt
Refined carbohydrates
Alcohol (in excess)
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cardiovascular risk is particularly high. A secondary,
though very frequent and decisive objective in MS, obesity,
and DM, is to lower cholesterol, other than HDL
cholesterol, to levels <130 mg/dL (optional <100 mg/dL).
In order to prevent pancreatitis, triglycerides become a
primary target for treatment when they exceed 500
mg/dL.13,40
Statins are the drug of choice to lower LDL levels.
They have been shown to reduce serious cardiovascular
complications by 21% and 23% in diabetic and non-
diabetic patients, respectively, in both primary and
secondary prevention.41 Statins are therefore essential
treatment in patients with diabetes mellitus. The dose
should be based on the size of the reduction required in
LDL cholesterol. Any of the drugs in the group should
be suitable; the important thing is to pursue and achieve
the required dose and the targets set. 
Fibrates are considered more effective than statins in
lowering triglyceride and raising HDL levels, due to their
agonist effect on PPARα. They might therefore appear
to be an ideal treatment for atherogenic dyslipidemia in
diabetes mellitus.42 However, the FIELD study showed
that fenofibrate, one of the most widely used fibrates,
did not significantly reduce the risk of coronary events.43
This has led to its usefulness as a preventive treatment
being questioned. Nevertheless, fibrates are the primary
indication in hypertriglyceridemia (target value <150
mg/dL).
The primary indication for niacin, which is not available
in Spain, is to increase HDL concentrations, usually in
combination with a statin.44 Fibrates can also be used to
raise HDL cholesterol levels,40 although extreme care
should be taken if using them in combination with a statin
(fenofibrate in this case) because of the possibility of
myositis. This is particularly true in polymedicated patients
or those who have renal dysfunction.45
Antiplatelet Treatment
Diabetes, MS, and even obesity are all prothrombotic
conditions, with hyperaggregability and hypofibrinolysis.
Acetylsalicylic acid has been shown to prevent
atherothrombotic complications.46 The majority of clinical
practice guidelines therefore recommend doses of 81-
325 mg/day, unless contraindicated, in all patients with
diabetes and MS.14,26
Figure 9 summarizes overall preventive treatment for
cardiovascular and metabolic risk in patients with DM2,26
and which can be applied almost in their entirety to
patients with MS.13
SPECIFIC TREATMENTS 
Hyperglycemia 
The aim of glucose regulating treatment is to reduce
baseline blood glucose levels, glycohemoglobin (<7%),
and postprandial blood glucose levels. There is little data
available on treatment strategies in patients with MS with
respect to control of the carbohydrate mechanism. The
most appropriate drugs in obesity and MS are acarbose,
metformin, and the glitazones, administered alone or in
combination depending on the circumstances.26
As regards DM2, the ADA/EASD treatment algorithm
opts for strict control of glycohemoglobin using multiple
treatments (Figure 10).47 Several studies have
demonstrated that controlling glucose values can be an
effective preventive measure.48
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Obesity
Weight loss is associated with relevant reductions in
CVD whether DM2 is present or not.49 The ideal objective
is to reach a BMI of 25 (a more realistic value might be
<27) or a waist circumference under that indicated as the
threshold in the MS criteria.13 As well as diet and exercise,
some drugs are useful for weight reduction. To date, only
sibutramin and orlistat have been approved for use, though
both have poor outcomes and are only moderately well-
tolerated.50
Rimonabant is a selective CB1 receptor blocker which
has proven effective in achieving substantial weight loss
and in reducing triglyceride levels and glycohemoglobin.
It has also been shown to increase HDL cholesterol levels
in obese patients and specifically in patients with
diabetes.51-53 Its possible psychological side effects require
further study. 
Bariatric surgery is indicated in morbidly obese patients
or, in less advanced cases, when CVD or diabetes are
also present.54
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Figure 9. Overview of preventive treatment
in patients with diabetes,26 also applicable
in metabolic syndrome. ASA indicates
acetylsalicylic acid; CA, calcium antagonist;
ARA-II, angiotensin II receptor antagonist;
Bβ, beta-blockers; ED, erectile dysfunction;
CVD, cardiovascular disease; IMTC, intima-
media thickness of carotid artery; HDL,
high density lipoproteins; ACE, angiotensin
converting enzyme; BMI, body mass index;
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blood pressure; MDCT, multi-detector
computed tomography; TG, triglycerides.
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Vascular Complications
Peripheral vascular complications should be managed
using percutaneous or surgical procedures corresponding
to the condition in question. 
As regards cardio-ischemic complications, treatment
should be similar to that used in any other case of chronic
angina. Antianginal drugs and revascularization will be
used depending on level of functioning and coronary
anatomy. The classic antianginal drugs (nitrates, beta
blockers, and calcium antagonists) can all be used in
patients with MS, obesity, or DM2.28
In acute coronary syndromes, strict glucose control
using insulin perfusion is essential and has been shown
to reduce the incidence of some adverse outcomes.55 In
acute cases, the recommended values are as close as
possible to 110 mg/dL, and always <180 mg/dL.14 In
non-critical hospitalized patients, prandial insulin can be
used, with control values ranging from 90 to 130 mg/dL
(fasting) and <180 mg/dL after meals.14
Criteria for revascularization in patients with DM2 are
influenced by the greater risk (which requires the use of
more intensive treatments) and lower success rates
associated with revascularization procedures in these
patients.56,57
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